Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 2:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 691 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Corticosteroid Clear all

Conditions: Asthma
Interventions: Procedure: Investigational Procedures; Other
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 63
States / cities: Bessemer, Alabama • Chandler, Arizona • Mesa, Arizona + 49 more

Conditions: Graft-versus-Host Disease, Immune System Disorders
Interventions: Mycophenolate Mofetil, Placebo; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 36
States / cities: Duarte, California • La Jolla, California • Stanford, California + 28 more

Conditions: Cancer
Interventions: entinostat; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 3
States / cities: Bethesda, Maryland

Conditions: Multiple Sclerosis
Interventions: Methylprednisolone, Prednisone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Graft-Versus-Host Disease
Interventions: Pentostatin; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Asthma
Interventions: beclomethasone dipropionate; Drug
Lead sponsor: Henry Ford Health System; Other
Eligibility: 12 Years to 56 Years
Enrollment: 362 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Allergic Asthma
Interventions: Placebo, Omalizumab, Immunotherapy; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF, VI, UMEC, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 14
States / cities: Mobile, Alabama • Phoenix, Arizona • Huntington Beach, California + 11 more

Conditions: Thumb Osteoarthritis
Interventions: Ketorolac, Triamcinolone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Osteoarthritis of the Knee
Interventions: Cooled Radiofrequency, Corticosteroid injection; Device · Drug
Lead sponsor: Halyard Health; Industry
Eligibility: 21 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 11
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Santa Monica, California + 8 more

Conditions: Graft-versus-Host Disease
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Graft Vs Host Disease, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease
Interventions: Exercise, Attention control; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler, Placebo inhalation powders via ELLIPTA inhaler, Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler, Placebo inhalation powder via ACCUHALER/DISKUS inhaler, Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 1,526 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 34
States / cities: Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more

Conditions: Alcoholic Hepatitis
Interventions: IDN-6556, Placebo; Drug
Lead sponsor: Conatus Pharmaceuticals Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Indianapolis, Indiana • Rochester, Minnesota • Richmond, Virginia

Conditions: Renal Transplantation
Interventions: Alemtuzumab, rabbit antithymocyte globulin, Belatacept, Tacrolimus, Mycophenolate mofetil, early cessation of steroids; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 8
States / cities: San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more

Conditions: Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
Interventions: Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 81
States / cities: Phoenix, Arizona • La Jolla, California • Madera, California + 60 more

Conditions: Carcinoma, Adrenal Cortical
Interventions: Etoposide, Doxorubicin, Cisplatin, Streptozotocin, Mitotane; Drug
Lead sponsor: Collaborative Group for Adrenocortical Carcinoma Treatment; Other
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Bethesda, Maryland • Ann Arbor, Michigan

Conditions: End Stage Renal Disease
Interventions: Rabbit Antithymocyte globulin, Daclizumab; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Knee Osteoarthritis
Interventions: Ketorolac, Betamethasone; Drug
Lead sponsor: St. Luke's Hospital, Pennsylvania; Other
Eligibility: 18 Years and older · Male only
Enrollment: 448 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Bethlehem, Pennsylvania

Conditions: Stenosing Tenosynovitis
Interventions: Amniotic fluid injection, Steroid injection; Biological
Lead sponsor: J&M Shuler; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Allergic Asthma
Interventions: omalizumab at a dose of 0.016mg/kg/IU/mL, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • St Louis, Missouri • Durham, North Carolina + 2 more

Conditions: Asthma
Interventions: Xolair; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Eclampsia
Interventions: Dexamethasone; Drug
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Rhinitis, Allergic, Perennial
Interventions: GW685698X aqueous nasal spray; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 12
States / cities: Hot Springs, Arkansas • Little Rock, Arkansas • Long Beach, California + 9 more

Search by objective public record fields.

A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice

Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-Ethnicity (SAPPHIRE)

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2

NSAID Injection Versus Corticosteroid Injection for Basilar Thumb Arthritis

Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

Belatacept Early Steroid Withdrawal Trial

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)

Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists

Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections

Corticosteroid vs. Amniotic Fluid Injections in Patients With Trigger Finger

Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists

Safety and Efficacy Study of Omalizumab Given Prior to Immunotherapy

Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):

A Study Of GW685698X For The Treatment Of Perennial Allergic Rhinitis In Pediatrics